Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Louisiana: - Louisiana Hematology Oncology Associates LLC — Baton Rouge, Louisiana
- Mary Bird Perkins Cancer Center - Covington — Covington, Louisiana
- Ochsner Hematology Oncology North Shore - Covington (West Region) — Covington, Louisiana
- Louisiana State University Health Science Center — New Orleans, Louisiana
- University Medical Center New Orleans — New Orleans, Louisiana
Phase 3 Recruiting Network
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it dev…
Sponsor: Children's Oncology Group
NCT ID: NCT03067181
Sites in Louisiana: - University Medical Center New Orleans — New Orleans, Louisiana
- Children's Hospital New Orleans — New Orleans, Louisiana
- Ochsner Medical Center Jefferson — New Orleans, Louisiana
Phase 3 Recruiting Network
This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part o…
Sponsor: Children's Oncology Group
NCT ID: NCT06513962
Sites in Louisiana: - Children's Hospital New Orleans — New Orleans, Louisiana
- Ochsner Medical Center Jefferson — New Orleans, Louisiana
Phase 3 Recruiting Industry
This is a clinical study that has two parts. It is testing a potential new medicine called Sofetabart Mipitecan (LY4170156) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A looks at participants whos…
Sponsor: Eli Lilly and Company
NCT ID: NCT07213804
Sites in Louisiana: - Ochsner Clinic Foundation — New Orleans, Louisiana
- Trials 365 — Shreveport, Louisiana
Phase 3 Recruiting Industry
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallo…
Sponsor: AbbVie
NCT ID: NCT05445778
Sites in Louisiana: - Louisiana State University Health Sciences Center - New Orleans /ID# 269559 — New Orleans, Louisiana
- Ochsner Medical Center - Jefferson Highway /ID# 269530 — New Orleans, Louisiana
Phase 3 Recruiting Industry
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Sponsor: Verastem, Inc.
NCT ID: NCT06072781
Sites in Louisiana: - Louisiana State University — New Orleans, Louisiana
Phase 3 Recruiting Industry
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer get…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06824467
Sites in Louisiana: - Women's Cancer Care ( Site 0067) — Covington, Louisiana
Phase 3 Recruiting Industry
This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expr…
Sponsor: Daiichi Sankyo
NCT ID: NCT06819007
Sites in Louisiana: - Trials365 LLC — Shreveport, Louisiana
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Louisiana: - East Jefferson General Hospital — Metairie, Louisiana
- University Medical Center New Orleans — New Orleans, Louisiana
- Ochsner Medical Center Jefferson — New Orleans, Louisiana
Phase 2 Recruiting NIH
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite tre…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554328
Sites in Louisiana: - Ochsner Baptist Medical Center — New Orleans, Louisiana
- Ochsner Medical Center Jefferson — New Orleans, Louisiana
Phase 2 Recruiting Industry
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with fo…
Sponsor: AbbVie
NCT ID: NCT06890338
Sites in Louisiana: - Women'S Cancer Care /ID# 276469 — Covington, Louisiana
- University Medical Center New Orleans /ID# 274755 — New Orleans, Louisiana
- Trials 365 /ID# 274310 — Shreveport, Louisiana
Phase 2 Recruiting Industry
This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.
Sponsor: Incyte Corporation
NCT ID: NCT07023627
Sites in Louisiana: - Trials365, Llc — Shreveport, Louisiana
Phase 1, Phase 2 Recruiting Industry
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…
Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in Louisiana: - Louisiana State University Health Sciences Center — New Orleans, Louisiana
Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.
Sponsor: Cybrexa Therapeutics
NCT ID: NCT06315491
Sites in Louisiana: - Women's Cancer Care — Covington, Louisiana
Phase 1, Phase 2 Recruiting Industry
This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents
Sponsor: AstraZeneca
NCT ID: NCT05123482
Sites in Louisiana: - Research Site — Shreveport, Louisiana
Phase 2 Recruiting Industry
Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). Approximately 60 participants will be enrolled. The study will assess the effi…
Sponsor: MacroGenics
NCT ID: NCT06730347
Sites in Louisiana: - Ochsner MD Anderson Cancer Center — New Orleans, Louisiana
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Louisiana: - LSU Health Baton Rouge-North Clinic — Baton Rouge, Louisiana
- Our Lady of the Lake Physician Group — Baton Rouge, Louisiana
- Our Lady of The Lake — Baton Rouge, Louisiana
- Louisiana Hematology Oncology Associates LLC — Baton Rouge, Louisiana
- Louisiana Hematology Oncology Associates — Baton Rouge, Louisiana
NA Recruiting Academic/Other
This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves…
Sponsor: NRG Oncology
NCT ID: NCT04251052
Sites in Louisiana: - West Jefferson Medical Center — Marrero, Louisiana
- Louisiana State University Health Science Center — New Orleans, Louisiana
- University Medical Center New Orleans — New Orleans, Louisiana
- Willis-Knighton Medical and Cancer Center — Shreveport, Louisiana
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Louisiana: - Massive Bio SYNERGY-AI site — New Orleans, Louisiana
Recruiting Academic/Other
The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus…
Sponsor: Mayo Clinic
NCT ID: NCT05051722
Sites in Louisiana: - Ochsner Clinic Foundation — New Orleans, Louisiana